We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NASDAQ:AZN | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.23 | -0.30% | 76.18 | 76.16 | 76.20 | 319,750 | 14:26:30 |
From May 2019 to May 2024
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that Symbicort was approved in China as a treatment for mild asthma in patients over the age of 12.
The U.K. pharmaceutical giant said the approval by the National Medical Products Administration was based on the positive results of the SYGMA 1 and SYGMA 2 Phase 3 trials. Those evaluated the efficacy of Symbicort Turbuhaler taken, as needed, as an anti-inflammatory reliever compared with the standard of care therapies in mild asthma, the company said.
The company said Symbicort was already approved in China for patients with moderate to severe asthma.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
January 26, 2021 02:32 ET (07:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
